Hossein Motedayyen

Dr. Hossein Motedayyen


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2017 in BMC Research Notes
Verified
Journal Article
Open access
PDF file
HMHossein Motedayyen
Hossein Motedayyen
NENafiseh Esmaeil
Nafiseh Esmaeil
NTNader Tajik
Nader Tajik
FKFahimeh Khadem
Fahimeh Khadem
SGSomayeh Ghotloo
Somayeh Ghotloo
ARAbbas Rezaei
Abbas Rezaei
Human amniotic epithelial cells (hAECs) which are isolated from the amniotic membrane have stem cell-like properties and immunomodulatory effects. Several protocols have been proposed for isolation of hAECs, nevertheless, there is no report concerning isolation of highly viable hAECs, with desirable yield, and without significant purity reduction. In the current study, a detailed protocol with some modification of previous ones is presented in which the amendments led to isolation of hAECs with high purity, yield and viability. Moreover, isolated hAECs were subjected to immuno-phenotyping and their physiological status was assessed using a proliferation assay. The average yield of obtained hAECs using the new modified method was 190 × 106 cells with a mean viability of 87%, with less than 1% contamination with mesenchymal stem cells (MSCs). The isolated cells were > 95% positive for the epithelial cell markers. The lowest initial plating efficiency of the cells was 80%. Freshly isolated hAECs had the ability to proliferate for 5–6 passages in a standard culture medium.

1 January 2020 in International Journal of Immunopathology and Pharmacology
Verified
Journal Article
Open access
PDF file
FFFarshid Fathi
Farshid Fathi
RSRamin Sami
Ramin Sami
SMSamaneh Mozafarpoor
Samaneh Mozafarpoor
HHHossein Hafezi
Hossein Hafezi
HMHossein Motedayyen
Hossein Motedayyen
NEnahid eskandari
nahid eskandari
Coronavirus disease 2019 (COVID-19), an acute respiratory infection, is largely associated with dysregulation and impairment of the immune system. This study investigated how the immune system changes were related to disease severity in COVID-19 patients. The frequencies of different immune cells and levels of pro- and anti-inflammatory cytokines in whole blood of participants were determined by flow cytometry and enzyme-linked immunosorbent assay, respectively. The values of other inflammatory agents were also studied. In the late recovery stage, unlike CD56high CD16+/− NK cells and monocytes, CD56low CD16+ NK cell numbers were increased ( P < 0.0001–0.05). Th1, Th2, and Th17 cell percentages were significantly lower in patients than healthy control ( P < 0.0001–0.05), while their frequencies were increased following disease recovery ( P < 0.0001–0.05). The numbers of Tregs, activated CD4+ T cells, and exhausted CD8+ T cells were significantly decreased during a recovery ( P < 0.0001–0.05). No significant change was observed in exhausted CD4+ T cell number during a recovery ( P > 0.05). B cell showed an increased percentage in patients compared to healthy subjects ( P < 0.0001–0.05), whereas its number was reduced following recovery ( P < 0.0001–0.05). IL-1α, IL-1β, IL-6, TNF-α, and IL-10 levels were significantly decreased in the late recovery stage ( P < 0.0001–0.05). However, TGF-β1 level was not significantly changed during the recovery ( P > 0.05). Lymphocyte numbers in patients were significantly decreased ( P < 0.001), unlike ESR value ( P < 0.001). Lymphocyte number was negatively correlated to ESR value and Th2 number ( P < 0.05), while its association with monocyte was significantly positive at the first day of recovery ( P < 0.05). The immune system changes during the disease recovery to improve and regulate immune responses and thereby may associate with the reduction in disease severity.

17 December 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
FRFatemeh Rezaei-Tazangi
Fatemeh Rezaei-Tazangi
HRHossein Roghani-Shahraki
Hossein Roghani-Shahraki
MGMahdi Khorsand Ghaffari
Mahdi Khorsand Ghaffari
FZFiroozeh Abolhasani Zadeh
Firoozeh Abolhasani Zadeh
ABAynaz Boostan
Aynaz Boostan
HMHossein Motedayyen
Hossein Motedayyen
Ovarian cancer (OCa) is characterized as one of the common reasons for cancer-associated death in women globally. This gynecological disorder is chiefly named the “silent killer” due to lacking an association between disease manifestations in the early stages and OCa. Because of the disease recurrence and resistance to common therapies, discovering an effective therapeutic way against the disease is a challenge. According to documents, some popular herbal formulations, such as curcumin, quercetin, and resveratrol, can serve as an anti-cancer agent through different mechanisms. However, these herbal products may be accompanied by some pharmacological limitations, such as poor bioavailability, instability, and weak water solubility. On the contrary, using nano-based material, e.g., nanoparticles (NPs), micelles, liposomes, can significantly solve these limitations. Therefore, in the present study, we will summarize the anti-cancer aspects of these herbal and-nano-based herbal formulations with a focus on their mechanisms against OCa.

1 November 2020 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Closed access
RKReza Daneshvar Kakhki
Reza Daneshvar Kakhki
MDMaryam Dehghanei
Maryam Dehghanei
RAReza Arefnezhad
Reza Arefnezhad
HMHossein Motedayyen
Hossein Motedayyen

1 April 2021 in Cytokine
Verified
Journal Article
Closed access
RSRamin Sami
Ramin Sami
FFFarshid Fathi
Farshid Fathi
NEnahid eskandari
nahid eskandari
MAMeysam Ahmadi
Meysam Ahmadi
RAReza ArefNezhad
Reza ArefNezhad
HMHossein Motedayyen
Hossein Motedayyen

12 August 2024 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
ACAmir Modarresi Chahardehi
Amir Modarresi Chahardehi
HOHamid Reza Ojaghi
Hamid Reza Ojaghi
HMHossein Motedayyen
Hossein Motedayyen
RAReza Arefnezhad
Reza Arefnezhad
Psoriasis, a persistent immune-mediated inflammatory skin condition, affects approximately 2-3% of the global population. Current treatments for psoriasis are fraught with limitations, including adverse effects, high costs, and diminishing efficacy over time. Thymoquinone (TQ), derived from Nigella sativa seeds, exhibits promising anti-inflammatory, antioxidant, and immunomodulatory properties that could prove beneficial in managing psoriasis. However, TQ’s hydrophobic nature and poor bioavailability have hindered its usefulness as a therapeutic agent. Recent research has strategically addressed these challenges by developing nano-thymoquinone (nano-TQ) formulations to enhance delivery and efficacy in treating psoriasis. Preclinical studies employing mouse models have demonstrated that nano-TQ effectively mitigates inflammation, erythema, scaling, epidermal thickness, and cytokine levels in psoriatic lesions. Various nano-TQ formulations, including nanoemulsions, lipid vesicles, nanostructured lipid carriers, and ethosomes, have been explored to improve solubility, facilitate skin penetration, ensure sustained release, and achieve site-specific targeting. Although clinical trials are currently scarce, the outcomes from in vitro and animal models are promising. The potential co-delivery of nano-TQ with other anti-psoriatic agents also presents avenues for further investigation.